Plunkett Research Online: Neuphoria Therapeutics Inc

NEUPHORIA THERAPEUTICS INC (NEUP:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modul.....



Neuphoria Therapeutics Inc
Ticker: NEUP
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 08 8354 6100
Fax: 08 8354 6199
Address: 100 Summit Dr
Burlington, MA 01803 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Preparation Manufacturing
Contacts Description
Spyros PapapetropoulosCEO/Director/President
Timothy CunninghamCFO
See More
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modul.....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202420232022202120202019
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
NameTitleSalary (AUD)Bonus (AUD)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: